Qicong Sheng, Social Media Consultant at JACC CardioOncology at JACC Journals, shared on LinkedIn:
“A new primer on Antibody-Drug Conjugate (ADC) cardiotoxicity in breast cancer was released on JACC!
Key takeaways:
- ADCs have rapidly transformed the therapeutic landscape of breast cancer and are increasingly evaluated for curative intent. The antibody, linker, and cytotoxic payload each contribute to cardiovascular toxicity risk.
- In HER-2-directed conjugates, trastuzumab deruxtecan (T-DXd) shows higher and more variable rates of LVEF decline compared with trastuzumab emtansine (T-DM1).
- TROP-2-directed conjugates, such as sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd), exhibit low overall cardiac toxicity risk, though ongoing surveillance remains essential.
Future prospective studies and tailored clinical surveillance are important for maximizing the therapeutic benefits of these therapies while protecting patients’ heart health.”
Title: Cardiovascular Toxicity of Antibody-Drug Conjugates in Breast Cancer: Current Evidence and Evolving Considerations: JACC: CardioOncology Primer
Authors: Heather Moore, Laura A. Huppert, Javid J. Moslehi, Eric H. Yang, Sarah Hatcher, Alexandra Thomas
Read the full article.
You can also explore: Trastuzumab-Related Cardiotoxicity: 2-Fold Higher Risk Linked to CHIP